Strongyloides Stercoralis Public Health Control in Rwanda
SCAN
Integration of Strongyloides Stercoralis Public Health Control Into the Soil-transmitted Helminths Control Programme in Rwanda - The SCAN Study
1 other identifier
observational
1,415
1 country
1
Brief Summary
The World Health Organization (WHO) recently issued guideline for the public health control of Strongyloides stercoralis in endemic areas. We aimed to evaluate the feasibility of implementing the WHO recommendations in Rwanda, specifically to intergrate the activities for the public health control of strongyloidiasis in the ongoing national programme for the control of the other soil-transmitted helminths and schistosomiasis, that has been in place for several years. As additional objective, we aimed to estimate the prevalence of S. stercoralis in two districts of Rwanda (Gisagara and Rubavu). To evaluate the feasibility, we asked lab technicians to evaluate challenges emerged during the implementation of the laboratory procedures with a structured questionnaire. Also, we evaluated the costs needed to perform these tests. We estimated the prevalence of S. stercoralis by calculating the number of positive cases out of all people tested. The lab technicians participated to a training session, where they were taught the S. stercoralis-specific lab techniques, and to a two-day pilot study where they could practice. The tests used were parasitological techniques (agar stool culture, (APC) and Baermann method) and an antibody rapid diagnostic test (RDT). Duration of training, with a specific focus on larvae differentiation, was identified as pivotal for a successful implementation of the parasitological techniques. The use of the RDT was instead considered easy to apply at all evaluation time points. Raw cost (i.e. not including staff salaries and transport costs) of materials and equipment was below 2 euros/test for each assay. In both districts, Strongyloides prevalence was below the threshold recommended by the WHO for the implementation of mass treatment, hence this aspect was not evaluated.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P75+ for all trials
Started Sep 2024
Shorter than P25 for all trials
1 active site
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
Study Start
First participant enrolled
September 23, 2024
CompletedPrimary Completion
Last participant's last visit for primary outcome
October 11, 2024
CompletedStudy Completion
Last participant's last visit for all outcomes
October 14, 2024
CompletedFirst Submitted
Initial submission to the registry
May 17, 2025
CompletedFirst Posted
Study publicly available on registry
June 6, 2025
CompletedJune 6, 2025
June 1, 2025
18 days
May 17, 2025
June 3, 2025
Conditions
Outcome Measures
Primary Outcomes (1)
Evaluation of the tests based on technicians' perception (through questionnaire) and costs
Technicians' previous experience with each S. stercoralis-specific assay, along with their perceptions regarding the ease of each of the procedural steps and associated safety concerns were assessed using a structured questionnaire. Each procedural step was rated as "Very easy", "Easy", "Neutral", "Difficult" and "Very difficult". For the steps marked "difficult" or "very difficult", respondents could specify the reasons for the difficulty from a predefined non-mutually-exclusive list of options. The per-test costs were calculated from the procurement records of each S. stercoralis-specific assay.
The data will be collected at baseline, during the pilot study (two - three days from baseline) and during field work (after two to three weeks from baseline)
Secondary Outcomes (1)
Prevalence
through study completion
Interventions
The primary outcome was reported based on the technicians' answers collected with a structured questionnaire. The individuals screened underwent testing with the tests detailed above
The primary outcome was based on the technicians' evaluation, based on their answers collected in a questionnaire. The individuals screened were tested with assays used for the national control programmes
Eligibility Criteria
People living in two districts in Rwanda
You may qualify if:
- People living in the selected districts and households
- Obtainment of written informed consent (for children's participation, consent was sought from parents/guardians).
You may not qualify if:
- Inability to supply an adequate stool sample
Contact the study team to confirm eligibility.
Sponsors & Collaborators
- IRCCS Sacro Cuore Don Calabria di Negrarlead
- University of Rwandacollaborator
- Rwanda Biomedical Centrecollaborator
Study Sites (1)
School of Health Sciences, College of Medicine and Health Sciences, University of Rwanda
Kigali, 737, Rwanda
MeSH Terms
Interventions
Intervention Hierarchy (Ancestors)
Study Design
- Study Type
- observational
- Observational Model
- OTHER
- Time Perspective
- CROSS SECTIONAL
- Target Duration
- 1 Day
- Sponsor Type
- OTHER
- Responsible Party
- PRINCIPAL INVESTIGATOR
- PI Title
- Head of infectious disease Clinical Research Unit
Study Record Dates
First Submitted
May 17, 2025
First Posted
June 6, 2025
Study Start
September 23, 2024
Primary Completion
October 11, 2024
Study Completion
October 14, 2024
Last Updated
June 6, 2025
Record last verified: 2025-06
Data Sharing
- IPD Sharing
- Will not share